SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from SINOVAC BIOTECH LTD (SVA) (CIK 0001084201) (SVA) — Nov 1, 2005

SINOVAC BIOTECH LTD (SVA) (CIK 0001084201)
Date: Nov. 1, 2005 · CIK: 0001084201 · Accession: 0001127855-05-000668

AI Filing Summary & Sentiment

Referenced dates: OCTOBER 12, 2005, October 12, 2005

Date
October 31, 2005
Author
Not clearly detected
Form
CORRESP
Company
SINOVAC BIOTECH LTD (SVA) (CIK 0001084201)

Letter

Via EDGAR SECURITIES AND EXCHANGE COMMISSION 450 Fifth Street, N.W. Washington, D.C. U.S.A., 20549-0405 Attention: Mr. Mark Brunhofer, Staff Accountant, Division of Corporation Finance

Dear Mr. Brunhofer:

Re:

Sinovac Biotech Ltd. (the “Company”)

File No. 1-32371

INTENDED TIMING OF FILING OF AMENDED FORM 20-F IN ACCORDANCE WITH SEC COMMENT LETTER DATED OCTOBER 12, 2005

We are counsel for the above-referenced Company and are writing on its behalf. We are writing to advise the Securities and Exchange Commission (the “SEC”) that the Company was unable to file an amended Annual Report to the Form 20-F/A-2 that was filed on September 21, 2005, within 10 business days as set forth in the comments of the reviewing staff of the SEC ‘s comment letter dated October 12, 2005, and we anticipate that an amended Annual Report on Form 20-F/A-3 will be filed on or around November 22, 2005.

Association of Law Corporations

Securities and Exchange Commission

October 31, 2005

Page 2

On behalf of the Company we sincerely thank and appreciate the SEC’s ongoing cooperation in this matter.

Yours very truly,

DEVLIN JENSEN

Per:

/s/ Mike Shannon

MICHAEL T. SHANNON

Show Raw Text
CORRESP
1
filename1.htm

		Untitled Page

			Vancouver Office:

			D     E     V     L    I     N

			P.O. Box 12077

			J     E    N     S     E     N

			Suite 2550

			Barristers & Solicitors

			555 West Hastings St.

			Vancouver, B.C.

						Canada V6B 4N5

						Tel: (604) 684-2550

						Fax: (604) 684-0916

						E-mail: mshannon@devlinjensen.com

				File Reference:   4020\045a

				Via EDGAR

				October 31, 2005

				SECURITIES AND EXCHANGE COMMISSION

					450 Fifth Street, N.W.

				Washington, D.C.

				U.S.A., 20549-0405

				Attention:        Mr. Mark Brunhofer, Staff Accountant, Division of Corporation Finance

					Dear Mr. Brunhofer:

					Re:

			Sinovac Biotech Ltd. (the “Company”)

				File No. 1-32371

					INTENDED TIMING OF FILING OF AMENDED FORM 20-F IN ACCORDANCE WITH SEC COMMENT LETTER DATED OCTOBER 12, 2005

			          We are counsel for the above-referenced Company and are writing on its behalf.  We are writing to advise the Securities and Exchange Commission (the “SEC”) that the Company was unable to file an amended Annual Report to the Form 20-F/A-2 that was filed on September 21, 2005, within 10 business days as set forth in the comments of the reviewing staff of the SEC ‘s comment letter dated October 12, 2005, and we anticipate that an amended Annual Report on Form 20-F/A-3 will be filed on or around November 22, 2005.

			Association of Law Corporations

			Securities and Exchange Commission

				October 31, 2005

			Page 2

			          On behalf of the Company we sincerely thank and appreciate the SEC’s ongoing cooperation in this matter.

			                                                                                                  Yours very truly,

				                                                                                                  DEVLIN JENSEN

					                                                                                                   Per:

				                                                                                                              /s/ Mike Shannon

				                                                                                                              MICHAEL T. SHANNON